|
https://www.marketwatch.com/story/cvs-health-to-initiate-tri… => ...CVS Health Corp. said Wednesday it was launching a new initiative to focused on chronic kidney disease, including early identification of kidney disease and the expansion of home dialysis. As part of the home dialysis program, CVS will initiate a clinical trial to demonstrate the safety and efficacy of a new hemodialysis device in support of a planned submission to the Food and Drug Administration to obtain market clearance. "Many patients believe in-center dialysis is their only kidney failure treatment choice, and do not know about patient-centered options, including home dialysis or kidney transplant," said Joseph Vassalotti, chief medical officer of the National Kidney Foundation. The stock, which slipped 0.9% in premarket trade, had slumped 17% over the past three months through Tuesday, while the S&P 500 had lost 4.0%. |
|
| aus der Diskussion: | AKTIEN IM FOKUS: Übernahme von Aetna setzen CVS-Health-Aktien unter Druck |
| Autor (Datum des Eintrages): | faultcode (04.04.18 14:16:42) |
| Beitrag: | 6 von 89 (ID:57459554) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |